FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296857> ?p ?o ?g. }

• W4286296857 endingPage "5084" @default.
• W4286296857 startingPage "5084" @default.
• W4286296857 abstract "5084 Background: Current management of HRLPC includes long-term ADT with primary RT. Despite definitive primary treatment, these pts have a high risk of metastasis and death. The phase 3 ATLAS study (NCT02531516) is investigating whether treatment intensification with the addition of APA to neoadjuvant and adjuvant treatment with gonadotropin-releasing hormone agonist (GnRHa) and external beam radiation therapy (EBRT) will improve metastasis-free survival (MFS) in high-risk pts. Here we describe (1) the distribution of baseline characteristics in this high-risk pt population and (2) the application of different RT regimens reflecting recent international guidelines and clinical practice changes for pts with HRLPC. Methods: Eligible HRLPC pts (Gleason score [GS] ≥ 8 or 7 and prostate-specific antigen [PSA] ≥ 20 ng/mL and stage ≥ cT2c), with ECOG PS 0/1 and Charlson Comorbidity Index (CCI) ≤ 3 are stratified by GS, pelvic nodal status, use of brachytherapy boost, and region; pts are randomized 1:1 to APA or PBO plus GnRHa for 30 (28-d) treatment cycles. Study treatment is applied neoadjuvant/concurrent to RT with APA 240 mg/d vs bicalutamide 50 mg/d for 4 cycles; another 26 cycles are completed adjuvantly after RT with APA 240 mg/d vs PBO. Primary end point is MFS (time from randomization to first distant metastasis on CT/MRI/bone scan by independent central review blinded to treatment or death from any cause). Imaging is conducted at baseline and q6m from biochemical failure until MFS. The protocol has been amended to include PET imaging (PSMA, fluciclovine, or choline). Results: Pts (N = 1503) were randomized at 266 sites in 24 countries in North America, Latin America, Europe, and Asia. The study is fully enrolled, but ongoing. Baseline characteristics for the total population: median age, 67 yrs; ECOG PS 0/1; 89%/11%; tumor classification at study entry: high-risk, 66%/very high–risk, 34%; median PSA, 6.3 ng/mL; cT2, 44%/cT3, 50%; cN1, 13%. In 90% of ATLAS pts, RT used was standard EBRT to prostate/pelvis over 6-8 weeks (cumulative 78-81 Gy); in 10%, recent hypofractionation schedules (per CHHiP or NRG/RTOG 0415) were applied (20x3 Gy/d or 28x2.5 Gy/d). 5.6% of pts had EBRT combined with brachytherapy (per ASCENDE-RT). Conclusions: Baseline characteristics of the ATLAS study population are reflective of pts with high- and very high–risk features and pelvic nodal involvement undergoing primary RT in clinical practice. The RT schedules applied reflect recent evidence and guideline changes for the use of hypofractionation in this pt population. ATLAS is an example of how RT can be included in phase 3 trials of HRLPC, in combination with next-generation androgen receptor inhibitors (eg, APA). Clinical trial information: NCT02531516." @default.
• W4286296857 created "2022-07-21" @default.
• W4286296857 creator A5000677310 @default.
• W4286296857 creator A5010579236 @default.
• W4286296857 creator A5011133286 @default.
• W4286296857 creator A5015365593 @default.
• W4286296857 creator A5017925159 @default.
• W4286296857 creator A5020692060 @default.
• W4286296857 creator A5025921361 @default.
• W4286296857 creator A5036003731 @default.
• W4286296857 creator A5045162411 @default.
• W4286296857 creator A5046488191 @default.
• W4286296857 creator A5049018134 @default.
• W4286296857 creator A5063584845 @default.
• W4286296857 creator A5072500672 @default.
• W4286296857 creator A5074343991 @default.
• W4286296857 creator A5077726848 @default.
• W4286296857 creator A5078572631 @default.
• W4286296857 creator A5085318253 @default.
• W4286296857 creator A5085716681 @default.
• W4286296857 creator A5088518998 @default.
• W4286296857 creator A5089481020 @default.
• W4286296857 date "2022-06-01" @default.
• W4286296857 modified "2023-10-03" @default.
• W4286296857 title "Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)." @default.
• W4286296857 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.5084" @default.
• W4286296857 hasPublicationYear "2022" @default.
• W4286296857 type Work @default.
• W4286296857 citedByCount "2" @default.
• W4286296857 countsByYear W42862968572022 @default.
• W4286296857 countsByYear W42862968572023 @default.
• W4286296857 crossrefType "journal-article" @default.
• W4286296857 hasAuthorship W4286296857A5000677310 @default.
• W4286296857 hasAuthorship W4286296857A5010579236 @default.
• W4286296857 hasAuthorship W4286296857A5011133286 @default.
• W4286296857 hasAuthorship W4286296857A5015365593 @default.
• W4286296857 hasAuthorship W4286296857A5017925159 @default.
• W4286296857 hasAuthorship W4286296857A5020692060 @default.
• W4286296857 hasAuthorship W4286296857A5025921361 @default.
• W4286296857 hasAuthorship W4286296857A5036003731 @default.
• W4286296857 hasAuthorship W4286296857A5045162411 @default.
• W4286296857 hasAuthorship W4286296857A5046488191 @default.
• W4286296857 hasAuthorship W4286296857A5049018134 @default.
• W4286296857 hasAuthorship W4286296857A5063584845 @default.
• W4286296857 hasAuthorship W4286296857A5072500672 @default.
• W4286296857 hasAuthorship W4286296857A5074343991 @default.
• W4286296857 hasAuthorship W4286296857A5077726848 @default.
• W4286296857 hasAuthorship W4286296857A5078572631 @default.
• W4286296857 hasAuthorship W4286296857A5085318253 @default.
• W4286296857 hasAuthorship W4286296857A5085716681 @default.
• W4286296857 hasAuthorship W4286296857A5088518998 @default.
• W4286296857 hasAuthorship W4286296857A5089481020 @default.
• W4286296857 hasConcept C121608353 @default.
• W4286296857 hasConcept C126322002 @default.
• W4286296857 hasConcept C126894567 @default.
• W4286296857 hasConcept C143998085 @default.
• W4286296857 hasConcept C168563851 @default.
• W4286296857 hasConcept C203092338 @default.
• W4286296857 hasConcept C2777899217 @default.
• W4286296857 hasConcept C2778043895 @default.
• W4286296857 hasConcept C2778311097 @default.
• W4286296857 hasConcept C2780192828 @default.
• W4286296857 hasConcept C2780962315 @default.
• W4286296857 hasConcept C2908647359 @default.
• W4286296857 hasConcept C509974204 @default.
• W4286296857 hasConcept C61367390 @default.
• W4286296857 hasConcept C71924100 @default.
• W4286296857 hasConcept C99454951 @default.
• W4286296857 hasConceptScore W4286296857C121608353 @default.
• W4286296857 hasConceptScore W4286296857C126322002 @default.
• W4286296857 hasConceptScore W4286296857C126894567 @default.
• W4286296857 hasConceptScore W4286296857C143998085 @default.
• W4286296857 hasConceptScore W4286296857C168563851 @default.
• W4286296857 hasConceptScore W4286296857C203092338 @default.
• W4286296857 hasConceptScore W4286296857C2777899217 @default.
• W4286296857 hasConceptScore W4286296857C2778043895 @default.
• W4286296857 hasConceptScore W4286296857C2778311097 @default.
• W4286296857 hasConceptScore W4286296857C2780192828 @default.
• W4286296857 hasConceptScore W4286296857C2780962315 @default.
• W4286296857 hasConceptScore W4286296857C2908647359 @default.
• W4286296857 hasConceptScore W4286296857C509974204 @default.
• W4286296857 hasConceptScore W4286296857C61367390 @default.
• W4286296857 hasConceptScore W4286296857C71924100 @default.
• W4286296857 hasConceptScore W4286296857C99454951 @default.
• W4286296857 hasFunder F4320337415 @default.
• W4286296857 hasIssue "16_suppl" @default.
• W4286296857 hasLocation W42862968571 @default.
• W4286296857 hasOpenAccess W4286296857 @default.
• W4286296857 hasPrimaryLocation W42862968571 @default.
• W4286296857 hasRelatedWork W1556752213 @default.
• W4286296857 hasRelatedWork W1985090107 @default.
• W4286296857 hasRelatedWork W2019482693 @default.
• W4286296857 hasRelatedWork W2093549003 @default.
• W4286296857 hasRelatedWork W2094355087 @default.
• W4286296857 hasRelatedWork W2398122810 @default.
• W4286296857 hasRelatedWork W2600999145 @default.
• W4286296857 hasRelatedWork W3181121802 @default.
• W4286296857 hasRelatedWork W4246611045 @default.

• next